Generally, the active-control trial design to report about ancillary benefits as a secondary objective.
The noninferiority trial should be assessed only if the new tx report advantages in safety, tolerability, convenience, cost, or some other important side that justify its use in place of the std tx. So, at least the new tx should have acceptable safety and tolerability, and the evidence in support of these ancillary benefits. That should be described in a published report.